- Home
- MODD vs ALXO Comparison
MODD vs ALXO Comparison
Compare MODD & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ALXO
- Stock Information
- Founded
- MODD 1998
- ALXO 2015
- Country
- MODD United States
- ALXO United States
- Employees
- MODD N/A
- ALXO N/A
- Industry
- MODD Industrial Specialties
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- ALXO Health Care
- Exchange
- MODD Nasdaq
- ALXO Nasdaq
- Market Cap
- MODD 67.4M
- ALXO 76.5M
- IPO Year
- MODD N/A
- ALXO 2020
- Fundamental
- Price
- MODD $1.55
- ALXO $2.00
- Analyst Decision
- MODD Buy
- ALXO Strong Buy
- Analyst Count
- MODD 1
- ALXO 5
- Target Price
- MODD $5.00
- ALXO $13.25
- AVG Volume (30 Days)
- MODD 235.8K
- ALXO 1.1M
- Earning Date
- MODD 02-11-2025
- ALXO 11-07-2024
- Dividend Yield
- MODD N/A
- ALXO N/A
- EPS Growth
- MODD N/A
- ALXO N/A
- EPS
- MODD N/A
- ALXO N/A
- Revenue
- MODD N/A
- ALXO N/A
- Revenue This Year
- MODD N/A
- ALXO N/A
- Revenue Next Year
- MODD $830.43
- ALXO N/A
- P/E Ratio
- MODD N/A
- ALXO N/A
- Revenue Growth
- MODD N/A
- ALXO N/A
- 52 Week Low
- MODD $1.08
- ALXO $1.19
- 52 Week High
- MODD $2.65
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- MODD 27.32
- ALXO 60.32
- Support Level
- MODD $1.45
- ALXO $1.40
- Resistance Level
- MODD $1.71
- ALXO $1.88
- Average True Range (ATR)
- MODD 0.09
- ALXO 0.19
- MACD
- MODD -0.00
- ALXO 0.02
- Stochastic Oscillator
- MODD 29.24
- ALXO 81.15
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.